Leadership

Leadership2018-07-05T22:32:54+00:00
Aaron Davenport
Aaron DavenportChairman
Mr. Davenport is a Managing Director at SK Capital and plays a leading role in all aspects of the firm’s investment strategy. He focuses on both the healthcare and specialty chemicals industries and currently serves as Chairman of Halo Pharmaceutical, AEB Group, Noramco, Inc. and Tasmanian Alkaloids and as a member of the Board of Directors of Archroma. He previously served on the Board of Directors of IBA Molecular. He joined the firm in 2010.

Prior to SK Capital, Mr. Davenport was a Principal at Arsenal Capital Partners where he co-led Arsenal’s healthcare investing efforts and served on the firm’s Operating and Investment Committees. Mr. Davenport’s professional career began in a general management role with CB Richard Ellis/Whittier Partners, where his leadership positions included Director of Business Strategy and Development.

Mr. Davenport was previously the Chairman of Charter Brokerage and previously served on the boards of Bend Research, IRIX Pharmaceuticals, Scientific Protein Laboratories, Priority Solutions, and Innovative Medical Device Solutions.

Mr. Davenport graduated magna cum laude with a B.A. in History from Amherst College and has an M.B.A. from the Tuck School of Business at Dartmouth College.

Lee Karras
Lee KarrasCEO
Lee Karras is an established pharmaceutical business executive with over twenty five years of healthcare industry related experience. Prior to joining Halo, Lee held executive leadership roles in several businesses. Most recently he was President of IBA Molecular North America, a global leader in the manufacture and distribution of generic radiopharmaceuticals.

Prior to IBA Molecular, Lee spent four years with AAIPharma Services where he was hired to reestablish the CDMO from bankruptcy and did so culminating in a successful $50MM sale to a private equity firm in 2009. Mr. Karras also spent 15 years with Cook Pharmaceutical Services and then Baxter Biopharma Solutions managing those successful CDMO businesses helping build the Baxter business into an a $200MM+ business during his tenure.

Lee has a proven track record of building scalable, yet cost effective businesses as well as managing complex contract research, manufacturing and pharmaceutical services businesses. Having worked in the contract pharmaceutical services industry over the last two decades, Lee has had to adapt and develop new business models to keep pace with the ever changing pharmaceutical landscape.

Lee holds a bachelors degree in Chemistry and an MS in Environmental Science, both from Indiana University in Bloomington.

Barry Lederman
Barry LedermanCFO
Barry Lederman has extensive financial and international pharmaceutical experience, having led teams of several public and private companies with global operations. Prior to joining Halo, he served as the Vice President and CFO for Eisai Inc. with operations in the Americas Region, the CFO at Wedgewood Pharmacy, Nycomed US Inc., and Qualitrol Company LLC (a subsidiary of Danaher Corporation).

Mr. Lederman also spent 10 years with Roche in positions of increasing responsibility within Finance, culminating in his appointment as Senior Vice President – Head of Business Analysis and Controlling at Roche Centralized Diagnostics, headquartered in Mannheim, Germany.

Mr. Lederman holds a Master of Business Administration with a dual concentration in Finance and Operations Management from the University of Rochester – Simon Business School and a Bachelor of Science degree in Electrical Engineering from the University of Rochester. In addition, he is a certified public accountant licensed in New Jersey and New York and gained his accounting experience at PwC. He also serves as a board member with the Northern New Jersey Council of the Boy Scouts of America.

Maryse Laliberté
Maryse LalibertéVP/General Manager Mirabel
Maryse brings overs 23 years’ experience in the development and the manufacture of pharmaceutical and biological products which included leadership roles in the characterization of proteins, technology transfer of cream, ointment, liquid and solid dosage form and, in-line support of external partner manufacturing of consumer care and drug products.

Prior to joining Halo, Maryse has worked in numerous roles in the pharmaceutical industry. Her most recent assignment was in the Global Technology Organization of Merck to support more than 35 external partners around the world producing consumer care products. Previously, Maryse was the Technical Service Director at Merck Canada site. She managed as GTO Director, the plant expansion, the installation and qualification of utilities, process and packaging equipment. Maryse was also involved in the transfer of multiple products in the Merck network. Maryse also supported the Schering Plough Canada site as Director of Production and Director of Quality Unit.

Maryse has a deep knowledge of EMEA, FDA, JP and HPFBI regulations. She has led numerous internal audits from different regulatory agencies and external manufacturing site audits for critical suppliers.
Maryse has a Master Degree in Biochemistry from the University of Quebec in Montreal, Canada. She is co-writer on several scientific publications and co-author on two patents.

James Cherry
James CherryVP/General Manager Whippany
Jim brings over 25 years’ experience in the technical transfer and commercial manufacture of pharmaceutical products. This experience includes leadership roles in manufacturing, validation and technology transfer of cream, ointment, liquid, gel and solid dosage forms.

Prior to joining Halo, Jim has worked in numerous roles in the pharmaceutical industry. His most recent assignment was at Fougera Pharmaceuticals where Jim held roles of Executive Director of Manufacturing Technology and Vice President of Manufacturing.  He was responsible for commercial manufacturing and support activities at two discrete manufacturing sites.   Previously, Jim was the Vice President of Manufacturing for Bradley Pharmaceuticals where he managed development, tech transfer, inventory, and manufacturing activities at multiple CMO’s and CDMO’s.   Jim spent a major portion of his career at PF Labs (Purdue Pharma) gaining experience in all facets of production operations for liquid, semi-solid and solid dose formulations.

Jim has a deep knowledge of FDA, DEA and OSHA regulations. He has led numerous projects including new product launches, implementation of Manufacturing Execution Systems, ERP systems, equipment and facility expansions.

Jim is a New Jersey, Registered Pharmacist with a BS in Pharmacy from Rutgers University.

Anthony Qu, PhD.
Anthony Qu, PhD.VP Pharmaceutical Development
Dr. Qu brings over 27 years of Research and Development and Project Management experience to Halo. Prior to joining Halo, Dr. Qu was the Director of Product Development at Patheon. While at Patheon, Dr. Qu lead and directed a group of 100+ scientific staff developing projects (NDA, 505B2, ANDA) for various clients. Dr. Qu oversaw the Formulation and Process Development, Analytical Development, Project Management and Clinical Packaging Departments. Successfully transferred more than 100+ projects from R&D to Commercial launches for domestic and international markets.

Prior to Patheon, Dr. Qu was Vice President, Scientific Affairs at Apotex, where he was responsible for managing the departments responsible for Formulation development, Analytical development, Regulatory affairs and Laboratory technical services.

Dr. Qu received his Bachelor and Master Degrees from Western China University of Medical Sciences in Medical Science. He earned his PhD from the University of Toronto in Biochemical Pharmacology. In addition, Dr. Qu holds several patents, and has published three books and more than a dozen scientific papers and abstracts.